KRAS and melanoma: Because NRAS Q61K, KRAS G13D, and MEK1 Q56P mutations are associated with BRAF inhibitor resistance in BRAF V600E melanoma, we first tested each A375 model cell line for resistance to the FDA-approved BRAF inhibitor compounds dabrafenib and vemurafenib in 2D tissue culture.